about
sameAs
Tumor immunotargeting using innovative radionuclidesA pretargeting system for tumor PET imaging and radioimmunotherapyComparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonographyPrognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsImprovement of radioimmunotherapy using pretargeting.Immuno-PET for Clinical Theranostic Approaches.PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.Vertebral osteomyelitis: an unusual presentation of Bartonella henselae infection.18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.Radioimmunoconjugates for the treatment of cancer.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Radioimmunotherapy for Treatment of Acute Leukemia.Report of the 6th International Workshop on PET in lymphoma.Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma.Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR.Gastric scintigraphy with a liquid-solid radiolabelled meal: performances of solid and liquid parameters.Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.[Venous leiomyosarcoma mimicking deep venous thrombosis: contribution of positron emission tomography].Comparison of gastric emptying scintigraphy based on the geometric mean of the gastric proportion of the abdominal radioactivity or on the geometric mean of the intragastric radioactivity
P50
Q28083230-7D8C76B5-2D10-4AAB-A312-006E24C7E013Q28087820-F9402818-08F0-4193-931D-DA5682F98788Q33388981-F205DB38-6EA6-4E03-A608-B19C094ABFB0Q33437608-A8F52B12-6AE5-4B16-B727-38339F8A8258Q34242100-F8C89A0C-AFD0-42E1-9CCF-B48688D08E40Q34931319-74CB8B99-7F48-4B79-BF95-7F3D7C89484AQ36088862-E6085734-BCB9-4E34-A24A-4A756DC781BDQ36323585-D8C56700-2C42-4AED-A3A0-8922E6CF2AF5Q36941931-A9B8BAF2-8A57-4053-9947-2C07276E5F05Q37631461-DA7BB0F1-2FE1-4180-BB0D-FCF2DFF0C0E7Q37691050-EB8C4307-86D3-40EF-BDF2-175FC843351DQ37917078-7344D785-D457-4B4C-9935-60A422EEFBE8Q38146479-2C0EE6F4-2138-46E9-B4BD-1FB3BF31354BQ38273846-57D129B9-7FAB-44BD-BB52-769B75A9ABEEQ38691472-090417CE-6103-4692-BDBB-F4B274E8ACB2Q38742247-A0F3878C-217C-418D-9DF0-A965A6EEC6A8Q38926460-AADF7861-C86C-4219-91E5-B2C689C810A1Q39519197-46B2AB14-D32A-401B-A1CF-174FFFD3B333Q39744448-454184F4-8C46-4E73-93DD-EC433E9F90C1Q39857869-3AF148BD-F1AA-4BEE-9B27-2EBDF8217F59Q41523153-BF822F09-0094-448D-8C7C-7A071200B6DFQ42238330-380230CB-CB94-4CE2-A81D-40CA8DA00B51Q43080849-F752C48E-0B49-497E-BFE8-14E022A52E32Q43122515-676C6692-0A18-44BB-A49A-BD895747B57FQ43581090-056C365A-32F2-4C12-AEEE-606064F38F05Q45003103-28E43616-0894-4EB6-BA0B-2B5F246C817DQ45981745-181F6694-9B60-4D15-8710-6A301756583AQ46562798-5AC16904-8825-40DB-ADFA-7EF190AB0F5BQ46725704-04877CBB-7405-427C-B90F-24FF4AC5CAC5Q46758798-0FE4AECE-075A-4103-99B1-8F57EEEF6D5EQ46863399-658416D3-71D6-416B-8EE8-4FE15E1ED180Q47212063-551C207C-AEC5-4D5A-B480-196C71FEBE66Q50586157-164CEDD2-F547-4A79-A06A-A17BDE54F6EAQ50996540-C4ADACB8-A2E7-47B1-9BFA-CC3FE720A8BEQ51027658-BB2089F6-8416-4F96-8351-0AC0896B92BAQ51983096-6CF5A40D-FC28-47D0-832D-A81E92EA4B8EQ53245208-07C5CD6F-DBC6-4F15-8DB9-15D61C03147EQ53276101-75283E67-5F7B-47F5-A2C6-941623724D73Q53380142-69798A5F-BF18-40C6-9827-9D23A245ABB6Q59376846-462B120F-202C-4C8C-82A4-457B44FB4643
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Caroline Bodet-Milin
@ast
Caroline Bodet-Milin
@en
Caroline Bodet-Milin
@es
Caroline Bodet-Milin
@nl
Caroline Bodet-Milin
@sl
type
label
Caroline Bodet-Milin
@ast
Caroline Bodet-Milin
@en
Caroline Bodet-Milin
@es
Caroline Bodet-Milin
@nl
Caroline Bodet-Milin
@sl
prefLabel
Caroline Bodet-Milin
@ast
Caroline Bodet-Milin
@en
Caroline Bodet-Milin
@es
Caroline Bodet-Milin
@nl
Caroline Bodet-Milin
@sl
P1053
F-7721-2013
P106
P21
P31
P3829
P496
0000-0002-8219-3592